Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new president and chief executive officer (CEO).

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Danish leader will face a challenging landscape among competitors ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries, has appointed Maziar Mike Doustdar as its new president and chief ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

The GLP-1 weight-loss drug giant just cut its investor guidance for 2025. Could the boom be over? Health-related stocks are not having a good day. First, America’s largest health insurance provider, ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Novo Nordisk's new CEO, Mike Doustdar, is considering layoffs as part of cost-saving measures. He aims to review all company expenses, including salaries, but assures a fair process. Doustdar, a ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...